Tyra Biosciences announced it will share initial Phase 2 clinical data for its oral FGFR3 inhibitor, dabogratinib, targeting intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) in September 2026. The company is also advancing trials for dabogratinib in achondroplasia and low-grade upper tract urothelial carcinoma, with key data expected through 2027. Tyra appointed Jonathan Day as EVP of Clinical Development to strengthen its skeletal dysplasia program. With $353.9 million in cash and securities, Tyra is funded through mid-2028 to support these developments and potential regulatory submissions.
Mama's Creations reported a strong Q2 fiscal 2027 with revenue up 55% to $54.6 million and net income doubling to $2.6 million. The company’s growth is driven by new product launches, effective cross-selling, and inclusion in Costco's national mailer...
VinFast Auto Ltd. is set to release its Q3 2026 earnings with analysts expecting a loss per share of $0.33 and revenues around $1.15 billion. The Vietnamese electric vehicle maker is expanding internationally, promoting its VF 9 SUV in Canada and ben...
FuboTV is positioned as a speculative buy, leveraging Disney's operational expertise and its controlling stake to improve performance. The integration of Hulu Live is expected to help FuboTV move from ongoing losses to achieving $300 million in adjus...
Zcash (ZEC) briefly surpassed the $1,000 mark, reaching a market value of $16.5 billion and entering the top ten cryptocurrencies by market cap. Trading volume surged by 173% to $1.62 billion, reflecting strong buying interest. However, the price soo...
Maria Bartiromo has publicly denied reports that she was fired from Fox News and Fox Business, calling such claims false and reckless. Fox News announced her departure after 12½ years without providing a reason, leading to speculation that she violat...
